VIP (etoposide, ifosfamide and cisplatinum) as a salvage intensification program in relapsed or refractory Hodgkin's disease

Bone Marrow Transplantation
V RibragP Carde

Abstract

Forty-two patients with refractory (15 patients) or relapsed (27 patients) Hodgkin's disease (HD) were included in a prospective single center study evaluating the efficacy of a regimen VIP combining etoposide 75 mg/m2/day days 1-5, ifosfamide 1.2 g/m2/day days 1-5 and cisplatinum 20 mg/m2/day days 1-5, one course every 4 weeks as salvage therapy in patients with refractory or relapsed Hodgkin's disease, potentially eligible for high-dose chemotherapy with reinjection of hematopoietic stem cells (HSC). If patients were considered chemosensitive after two courses of VIP, high-dose chemotherapy followed by the reinjection of HSC was planned. After two courses of VIP, 67% achieved an objective response including 38% complete responses. Overall, 28 patients went on to high-dose therapy with reinjection of HSC, and 46% of grafted patients are in a sustained complete remission. When the overall patient population is considered, 33% are in complete remission (CR) with a median follow-up of 37 months. A CR of less than 12 months and refractory disease were associated with a poor survival. These results showed that the VIP regimen is effective in relapsed or refractory HD and allows high-dose therapy to be given in the case of most resp...Continue Reading

Citations

Jul 10, 1999·Current Opinion in Hematology·R G Bociek, J O Armitage
Dec 17, 2009·Hematology·John Kuruvilla
Sep 8, 2015·Expert Review of Hematology·Komal Dumaswala, Amitkumar Mehta
Jun 1, 2009·Expert Review of Hematology·David Sibon, Pauline Brice
Jan 26, 2011·Blood·John KuruvillaMichael Crump
Jun 1, 2011·Einstein·Adriano de Moraes ArantesCésar Bariani
Aug 25, 2018·Expert Review of Hematology·Mayur NarkhedeBruce Cheson
Oct 19, 2001·Oncogene·J R Bradley, J S Pober
Nov 6, 2008·American Journal of Physiology. Endocrinology and Metabolism·Nabile BoukhettalaMoïse Coëffier
Feb 14, 2007·The Oncologist·Brian J Byrne, Jon P Gockerman
Dec 16, 2019·European Journal of Haematology·Sandro M WagnerChristian Sillaber

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.